Latest news with #AlpeshPatel
Time of India
23-04-2025
- Business
- Time of India
World Earth Day: Gujarat companies lead renewable energy shift
Representative Image AHMEDABAD: As the world observes Earth Day 2025 with the theme 'Our Power, Our Planet', Gujarat is once again emerging as a frontrunner—not just at the state policy level but also through the proactive efforts of local companies switching to clean energy. With a strong push for renewable sources like wind and solar, several Gujarat-based firms are walking the sustainability talk and gradually reducing their carbon footprint. Knack Packaging Limited, a leading exporter of plastic packaging materials to over 70 countries, currently draws 35% of its total power consumption from clean energy. This includes a 2.1 MW windmill at Rajkot and 2 MW of solar panels installed across its Ahmedabad plants. 'We are in the process of setting up an 11 MW solar farm near Khed Brahma–Ambaji, which will be operational by June-end. Post that, 80-90% of our plant's power will come from clean energy,' said Alpesh Patel , Director – Sales and Marketing. Patel adds that sustainability is no longer just an environmental goal but a business advantage as well, thanks to the improved affordability of solar technology. Specialty chemicals manufacturer Epigral Ltd has also turned to renewable energy under the state govt's hybrid policy. The company is sourcing 19 MW of solar and 19 MW of wind energy through joint ventures, meeting about 15% of its total energy requirement through renewables. 'Using renewable energy is crucial for the environment as well as competitiveness in current business practices. We are going to increase the share of renewable energy in our total consumption to 25% in the next two years,' said Maulik Patel , CMD of Epigral Ltd. Gujarat-based cotton spinning mills too have adopted renewable energy in a big way. 'As of now, around 50% of the spinning mills out of approximately 120 have installed 1.5 MW rooftop solar. Of these, nearly 35-40% have taken a larger leap by setting up ground-mounted solar plants, windmills, or adopting a hybrid model,' said Jayesh Patel , Senior Vice President, Spinners' Association Gujarat (SAG). He added that his own unit, Omax Cotspin, meets 90% of its electricity needs through installed solar and wind capacity. 'More and more spinning mills are adopting green energy because without renewable energy, viability is difficult. Also, our buyers in Europe insist that suppliers must use renewable energy,' he said. Soda ash maker GHCL is also making steady progress toward its sustainability targets, aiming to reduce Scope 1 and 2 carbon emissions by 30% by 2030 through internal carbon pricing and eco-conscious manufacturing practices. The company has already installed dedusting systems to improve air quality and relies on renewable energy for 75% of GHCL Textiles' operations. Across its facilities, 62.3 MW of wind and solar power are currently in use. However, industry players believe that regulatory support must keep pace. A common demand is the revision of the current 1 MW limit under net metering for industrial rooftop solar projects. Raising this cap, they argue, would accelerate the shift to renewables and further enable industries to invest in larger-scale green power systems.
Yahoo
06-02-2025
- Health
- Yahoo
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site
BROOMFIELD, Colo., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ('Aclarion' or the 'Company') (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced Northwestern Medicine as the initial site in the pivotal CLARITY trial, which is designed to demonstrate Nociscan's clinical and economic value in spine surgery. 'Northwestern Medicine is a leader in clinical trials. In 2024, Northwestern led over 6,900 clinical studies with 372,561 study participants,' said Alpesh Patel, MD, Professor and Co-Director of the Northwestern Center for Spine Health. 'We are pleased to participate in Aclarion's CLARITY trial, a groundbreaking randomized controlled trial examining Nociscan's impact on discogenic low back pain surgical outcomes. Low back pain is a complex problem and advancements like Nociscan are helping to advance our understanding of low back pain in fundamentally important ways.' Aclarion recently announced that the CLARITY trial is fully funded and will be led by Dr. Nicholas Theodore of Johns Hopkins as principal investigator. The CLARITY trial is a prospective, randomized multi-center study evaluating patients who are scheduled to undergo surgical treatment of 1- or 2- level discogenic low back pain. The study will enroll 300 patients at multiple high-volume sites across the US and all patients will receive a Nociscan prior to surgery. The study will be randomized at a 1:1 ratio of surgeons blinded-to-Nociscan and unblinded-to-Nociscan to guide the surgical treatment (Fusion / TDR). The primary endpoint is change in back pain as measured on a 100mm VAS Back at 12 months compared to baseline, with several secondary endpoints collected. 'We are pleased to launch the CLARITY trial with a prestigious institution like Northwestern and renowned spine expert Dr. Alpesh Patel. I saw firsthand from my earlier experiences commercializing algorithms in the cardiology space how well-designed clinical trials could drive the adoption of cloud-based, augmented intelligence platforms. When compared to traditional testing options, these technologies improved diagnostic accuracy, reduced unnecessary procedures and ultimately saved the health system significant costs,' said Brent Ness, CEO, Aclarion. 'At Aclarion, we are committed to building the same level of evidence to ensure adoption of Nociscan for all stakeholders is a logical and well-supported step for chronic low back pain.' Chronic low back pain is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain and has the potential to drive better surgical outcomes. For more information about CLARITY, please visit: CLARITY Trial To find a Nociscan center, view our site map here. For more information on Nociscan, please email: info@ This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any proxy, consent, vote or approval with respect to any securities of Aclarion, Inc. No offer, sale, issuance or transfer of securities shall be made in any jurisdiction in which such offer, sale, issuance or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Aclarion, Inc. Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ('MRS'), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as 'anticipates,' 'believes' and 'expects' or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contacts: Kirin M. Smith PCG Advisory, Inc. ksmith@ Media Contacts: Jennie Kim SPRIG Consulting jennie@ in to access your portfolio
